Circulating Tumor Cells (CTC) Market

Market Overview:

The global circulating tumor cells (CTC) market size reached US$ 10.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 20.0 Billion by 2028, exhibiting a growth rate (CAGR) of 10.2% during 2023-2028.

Circulating tumor cells (CTC) are cancer cells that split away from the primary tumor and appear in the circulatory system as singular units or clusters. They have different biological phenotypes, such as epithelial, mesenchymal, and mixed epithelial-mesenchymal. CTC levels in a patient's blood can allow early detection of cancer and act as a prognostic indicator. As they are in minimal quantity, several technologies are used for the isolation, enrichment, and detection of CTC, such as immunocapture, size-based separation, density-based separation, and microscopy. It also has wide-ranging applications in liquid biopsy, cancer research, drug development, and clinical biomarkers.

Circulating Tumor Cells (CTC) Market Trends:

The increasing prevalence of cancer due to genetic disorders, rising alcohol consumption, and rapid lifestyle changes are key factors driving the market growth. CTC assists in the early identification and real-time monitoring of lung, breast, digestive tract, and prostate cancer. In line with this, the increasing utilization of CTC in patient screening for metastasis and preclinical studies of new cancer drugs is favoring the market growth. Furthermore, the growing demand for minimally invasive (MI) diagnostic procedures and widespread adoption of CTC-based liquid biopsy to enable rapid recovery and limit trauma are providing a considerable boost to the market growth. Apart from this, the introduction of nanotechnology to improve the sensitivity and efficiency of CTC isolation and detection is providing an impetus to market growth. Moreover, increasing utilization in medical research to develop cell culture models for drug screening, disease modeling, genome editing, and tumor immunity is creating a positive outlook for the market. Additionally, the increasing awareness amongst healthcare professionals and patients about the importance of early cancer diagnosis is positively influencing the market growth. Other factors, including rapid advancements in biomedical imaging and bioengineering technology, extensive research and development (R&D) activities, and the rising demand for preventive medicine and companion diagnostics, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global circulating tumor cells (CTC) market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, application, product, specimen and end user.

Breakup by Technology:

• CTC Detection and Enrichment Method
• CTC Direct Detection Methods
• CTC Analysis
   

Breakup by Application:

• Clinical/Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell and Tumorigenesis Research
  • Drug/Therapy Development
     

Breakup by Product:

• Kits and Reagents
• Blood Collection Tubes
• Devices and Systems
   

Breakup by Specimen:

• Blood
• Bone Marrow
• Other Body Fluids
   

Breakup by End User:

• Hospital and Clinics
• Research and Academic Institutes
• Diagnostic Centres
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being BioFluidica Inc, Creatv MicroTech Inc., CytoLumina Technologies Corp., Fluxion Biosciences Inc., Greiner Bio-One International GmbH, Ikonisys Inc, Menarini Silicon Biosystems, Miltenyi Biotec, Qiagen N.V, Rarecells Diagnostics and Stemcell Technologies.

Report Coverage: